Allakos (NASDAQ:ALLK) initiated with Underperform rating and $34 (42% downside risk) price target at SMBC Nikko.
Avadel Pharmaceuticals (NASDAQ:AVDL) initiated with Buy rating and $14 (75% upside) price target at Stifel.
Krystal Biotech (NASDAQ:KRYS) initiated with Outperform rating and $73 (46% upside) price target at SMBC Nikko.
Momenta Pharmaceuticals (NASDAQ:MNTA) initiated with Neutral rating and $29 (10% upside) price target at Goldman Sachs.
Scholar Rock Holding (NASDAQ:SRRK) initiated with Outperform rating and $35 (136% upside) price target at Baird.
Jazz Pharmaceuticals (NASDAQ:JAZZ) upgraded to Outperform with a $166 (54% upside) price target at Bernstein.
Mirati Therapeutics (NASDAQ:MRTX) upgraded to Neutral with an $88 (14% upside) price target at JPMorgan.
Vanda Pharmaceuticals (NASDAQ:VNDA) upgraded to Buy with a $14 (32% upside) price target at Citigroup.
Teladoc (NYSE:TDOC) downgraded to Neutral with a $130 (5% downside risk) price target at Baird. Shares down 8% premarket.
https://seekingalpha.com/news/3550984-baird-cuts-view-on-teladoc-in-premarket-analyst-action
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.